Última actualización 12 de julio de 2026
Key finding
Carnosine supplementation had no effect on heart rate compared to placebo.
This study evaluated the effects of carnosine supplementation on cardiovascular and metabolic outcomes in adults with prediabetes and type 2 diabetes, finding no significant improvements.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the effects of carnosine supplementation on cardiovascular and metabolic outcomes in adults with prediabetes and type 2 diabetes, finding no significant improvements.
These findings are significant for clinicians and patients as they suggest that carnosine supplementation may not be an effective strategy for improving cardiovascular and metabolic health in individuals with prediabetes or type 2 diabetes. Understanding the limitations of such supplements can help guide treatment decisions and encourage reliance on more established interventions.
The sample size may limit the generalizability of the findings. The study only included adults with prediabetes and type 2 diabetes, which may not apply to other populations. The duration of supplementation may not have been sufficient to observe potential effects.
Published in
Publication details and source links for this paper.
Saeede S, James C, Kirthi M, et al. Carnosine Supplementation Does Not Improve Cardiovascular and Metabolic Outcomes in Adults with Prediabetes and Type 2 Diabetes. Nutrients. 2023;15(22):4835. doi:10.3390/nu15224835
Carnosine supplementation had no effect on heart rate compared to placebo.
Carnosine supplementation had no effect on peripheral blood pressure compared to placebo.
Carnosine supplementation had no effect on lipid parameters compared to placebo.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Acarbose and Carotid-femoral pulse wave velocity (cfPWV), Central blood pressure, Composite renal outcomes (kidney failure, sustained eGFR decline ≥57%, renal death), and 7 more.
This study contributes evidence to
Primary intervention
Acarbose
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
2
Related topics
10
Evidence pairs
37
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
Evidencia relacionada
Relación de evidencia
Guardar evidencia
Tema de evidencia
Guardar evidencia
Core evidence
The primary outcomes reported in this study.
Acarbose → Carotid-femoral pulse wave velocity (cfPWV)
Acarbose → Carotid-femoral pulse wave velocity (cfPWV)
Acarbose → Composite renal outcomes (kidney failure, sustained eGFR decline ≥57%, renal death)
Acarbose → Composite renal outcomes (kidney failure, sustained eGFR decline ≥57%, renal death)
Acarbose → Liver transient elastography
Acarbose → Liver transient elastography
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Alpha-glucosidase inhibitors and Carotid-femoral pulse wave velocity (cfPWV), Alpha-glucosidase inhibitors and Central blood pressure.
This study contributes to the evidence on the following intervention-outcome relationships.
Curated evidence collections and hubs this study is part of.
All studies on Alpha-glucosidase inhibitors
Contributes to Alpha-glucosidase inhibitors evidence base.
All studies measuring Carotid-femoral pulse wave velocity (cfPWV)
Measures Carotid-femoral pulse wave velocity (cfPWV) as a key outcome.
All studies measuring Central blood pressure
Measures Central blood pressure as a key outcome.
All studies measuring Lipid parameters
Measures Lipid parameters as a key outcome.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Current evidence does not show a clear benefit of Alpha-glucosidase inhibitors for Kidney Function.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Composite renal outcomes (kidney failure, sustained eGFR decline ≥57%, renal death)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Alpha-glucosidase inhibitors for Endothelial Function.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Endothelial function
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Acarbose for Carotid-femoral pulse wave velocity (cfPWV).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Carotid-femoral pulse wave velocity (cfPWV)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Acarbose for Central blood pressure.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Central blood pressure
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
